Platte River Capital’s Standard BioTools LAB Stock Holding History

Platte River Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-12,500	Closed	-$306K	–	173
2014 Q3	$306K	Buy	+12,500	New	+$351K	0.08%	162

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Platte River Capital's LAB Position: Q4 2014 in Review

Platte River Capital sold out of Standard BioTools (LAB) in Q4 2014, closing a stake of 12,500 shares — an estimated $306K sold.

Platte River Capital first reported a position in LAB in Q3 2014 and held it in 1 quarter. The position peaked at $306K in Q3 2014. 100 funds tracked by Wall St. Rank hold LAB as of Q4 2014.

Platte River Capital reported no remaining Standard BioTools position as of Q4 2014 after selling out during the quarter.
Platte River Capital sold 12,500 Standard BioTools shares in Q4 2014, an estimated $306K.
Platte River Capital first reported a position in Standard BioTools in Q3 2014 and held it in 1 quarter.
Platte River Capital's Standard BioTools position peaked at $306K in Q3 2014.
100 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2014.

Based on Platte River Capital's 13F filing for Q4 2014, filed 3 Feb 2015.